NCT02060656View on ClinicalTrials.gov

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

PHASE2UnknownINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

February 28, 2018

Study Completion Date

August 31, 2023

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Gemcitabine

1000mg/m2 IV D1, D8, D15 every 28 days

DRUG

Methylprednisolone

1000mg/m2 IV or PO D1-5 every 28 days

DRUG

Rituximab

375mg/m2 IV D1, D15 every 28 days

DRUG

Cisplatin

100mg/m2 IV D15 every 28 days

DRUG

Lenalidomide

25mg PO D1-21 every 28 days

Trial Locations (1)

SM2 5PT

Royal Marsden NHS Foundation Trust - London and Surrey, London

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER